Welcome to our dedicated page for Nrx Pharmaceuticals SEC filings (Ticker: NRXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical endpoints is challenging—especially when NRX Pharmaceuticals’ 10-K weaves FDA Fast-Track data, ketamine safety studies, and cash-runway calculations into more than 200 pages. If you have ever searched, “Where can I find NRX Pharmaceuticals’ quarterly earnings report 10-Q filing?” or “NRXP insider trading Form 4 transactions,” you know how time-consuming it can be.
Stock Titan solves this problem. Our AI-powered summaries translate dense NMDA receptor science into plain English, flagging trial milestones, manufacturing risks, and liquidity updates in seconds. You’ll see every filing type—10-K annual report, 10-Q quarterly results, 8-K material events, S-1 capital raises, and the proxy statement executive compensation section—updated in real time as soon as they hit EDGAR. Need to monitor NRX Pharmaceuticals Form 4 insider transactions real-time? We surface buying or selling by executives alongside context from the latest 8-K material events explained.
Investors tracking suicidal-depression therapies use our platform to:
- Compare R&D spend across quarters
- Spot language changes on pivotal trial outcomes
- Follow NRX Pharmaceuticals earnings report filing analysis for cash-burn trends
NRX Pharmaceuticals has formally requested the withdrawal of its Form S-1 Registration Statement (File No. 333-283220) that was initially filed on November 14, 2024. The company has decided not to proceed with its planned public offering at this time.
Key points:
- The withdrawal request was made pursuant to Rule 477(a) under the Securities Act of 1933
- The Registration Statement had not been declared effective by the SEC
- No securities were sold under this Registration Statement
- The request was signed by Jonathan Javitt, Chairman and Interim Chief Executive Officer
This withdrawal could signal a shift in the company's capital raising strategy or a response to market conditions. The decision to withdraw rather than proceed with the public offering may have implications for the company's growth plans and funding options.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has filed a Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission dated June 20, 2025. The filing enables the company to issue up to $150 million worth of securities—including common stock, preferred stock, debt securities, depositary shares, warrants, rights, purchase contracts and units—on a continuous or delayed basis under Rule 415.
The company is classified as a non-accelerated filer and smaller reporting company, indicating market capitalization under SEC thresholds. Its common stock last traded at $3.23 per share on June 18, 2025.
Under Rule 415(a)(6), the registration statement carries forward $90,592,307 of unsold securities from the prior shelf registration (File No. 333-265492, declared effective June 21, 2022). The associated filing fee of $8,397.91 is likewise carried forward. Once the new registration becomes effective, the prior shelf will be deemed terminated for the remaining unsold amount. Should any of these securities be sold before effectiveness, NRXP will file a pre-effective amendment to reconcile the balances.
NRx may sell securities through agents, underwriters, dealers or directly to investors; specific terms, pricing and net proceeds will be detailed in subsequent prospectus supplements or free-writing prospectuses. Investors are directed to the prospectus’ “Risk Factors” section and other incorporated documents for a full discussion of uncertainties related to the offering.
The flexibility afforded by the shelf facility provides NRXP with a mechanism to raise capital expediently as corporate needs arise, but it also introduces potential dilution and leverage considerations for existing shareholders.
FAQ
What is the current stock price of Nrx Pharmaceuticals (NRXP)?
What is the market cap of Nrx Pharmaceuticals (NRXP)?
What is the primary focus of NRX Pharmaceuticals?
What therapeutic areas does the company target?
What makes NRX-100 distinct from traditional ketamine formulations?
How does NRX-101 complement the company’s treatment strategy?
What role does HOPE Therapeutics play in the company’s strategy?
How does the company ensure quality in its clinical trials?
How does NRX Pharmaceuticals position itself in a competitive market?
What are the key benefits of NRX Pharmaceuticals’ technology platform?
